Key Highlights
- Johnson & Johnson integrates Shockwave Medical into its MedTech unit.
- Shockwave’s IVL technology to enhance cardiovascular disease treatment.
- Accretive to operating margin, with revenue growth acceleration.
Source: Business Wire
Notable Quotes
- “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory of cardiovascular disease, one of the leading causes of death globally. We are delighted to welcome the Shockwave team to Johnson & Johnson and look forward to bringing their innovative IVL technology to more patients around the world.” — Joaquin Duato, Chairman and Chief Executive Officer at Johnson & Johnson
- “Completing this acquisition is a significant milestone in the expansion of our leadership position in the medtech industry. Shockwave’s differentiated solutions and robust pipeline represent an exciting opportunity for Johnson & Johnson MedTech to bring more innovations to patients in one of the largest areas of unmet medical need. We are excited to begin collaborating directly with the Shockwave team and look forward to a bright future together.” — Tim Schmid, Executive Vice President and Worldwide Chairman at Johnson & Johnson MedTech
SoHC's Take
This acquisition marks a strategic expansion for Johnson & Johnson in the medtech sector, particularly in cardiovascular intervention. Shockwave Medical’s intravascular lithotripsy (IVL) technology complements Johnson & Johnson’s existing capabilities, positioning them as a leader in multiple high-growth markets within cardiovascular care. This move is expected to drive revenue growth and operational efficiencies, despite short-term impacts on earnings per share. The integration of Shockwave’s innovative solutions highlights Johnson & Johnson’s commitment to advancing medical technology and improving patient outcomes on a global scale.
